Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review

Abdollah, 2013, Extended pelvic lymph node dissection in prostate cancer: A 20-year audit in a single center, Ann Oncol, 24, 1459, 10.1093/annonc/mdt120 Bernstein, 2018, Contemporary incidence and outcomes of prostate cancer lymph node metastases, J Urol, 199, 1510, 10.1016/j.juro.2017.12.048 Parker, 2019, Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047] Messing, 2006, Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy, Lancet Oncol, 7, 472, 10.1016/S1470-2045(06)70700-8 Messing, 1999, Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer, N Engl J Med, 341, 1781, 10.1056/NEJM199912093412401 Preisser, 2019, The impact of lymph node metastases burden at radical prostatectomy, Eur Urol Focus, 5, 399, 10.1016/j.euf.2017.12.009 Abdollah, 2014, Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer, J Clin Oncol, 32, 3939, 10.1200/JCO.2013.54.7893 Touijer, 2014, Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy, Eur Urol, 65, 20, 10.1016/j.eururo.2013.03.053 Touijer, 2018, Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies, Eur Urol, 73, 890, 10.1016/j.eururo.2017.09.027 Moschini, 2016, Risk stratification of pN+ prostate cancer after radical prostatectomy from a large single institutional series with long-term followup, J Urol, 195, 1773, 10.1016/j.juro.2015.12.074 Moschini, 2016, Natural history of clinical recurrence patterns of lymph node-positive prostate cancer after radical prostatectomy, Eur Urol, 69, 135, 10.1016/j.eururo.2015.03.036 Zareba, 2017, Contemporary patterns of care and outcomes of men found to have lymph node metastases at the time of radical prostatectomy, J Urol, 198, 1077, 10.1016/j.juro.2017.06.062 Passoni, 2014, Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection, Urol Oncol, 32, 10.1016/j.urolonc.2012.10.009 Knoll, 2018, Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology, Eur Urol, 73, 290, 10.1016/j.eururo.2017.08.016 Moga, 2012 Ploussard, 2019, Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review, Eur Urol, 76, 493, 10.1016/j.eururo.2018.10.041 Mitropoulos, 2012, Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU Guidelines Panel assessment and recommendations, Eur Urol, 61, 341, 10.1016/j.eururo.2011.10.033 Schiavina, 2016, Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: a competing risk analysis of a multi-institutional database, Int J Urol, 23, 1000, 10.1111/iju.13203 Bianchi, 2018, Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: external validation on a multi-institutional database, Int J Urol, 25, 574, 10.1111/iju.13565 Nini, 2015, Patterns of clinical recurrence of node-positive prostate cancer and impact on long-term survival, Eur Urol, 68, 777, 10.1016/j.eururo.2015.04.035 Hussain, 2018, Phase III intergroup trial of adjuvant androgen deprivation with or without mitoxantrone plus prednisone in patients with high-risk prostate cancer after radical prostatectomy: SWOG S9921, J Clin Oncol, 36, 1498, 10.1200/JCO.2017.76.4126 Bravi, 2020, Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy, Urol Oncol, 38, 204, 10.1016/j.urolonc.2019.09.018 Cai, 2011, Clinical importance of lymph node density in predicting outcome of prostate cancer patients, J Surg Res, 167, 267, 10.1016/j.jss.2009.05.004 Mandel, 2017, Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment, World J Urol, 35, 1833, 10.1007/s00345-017-2079-4 Mandel, 2017, Association between lymph node counts and oncological outcomes in lymph node positive prostate cancer, Eur Urol Focus, 3, 248, 10.1016/j.euf.2016.02.018 Passoni, 2014, Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest LN metastasis, BJU Int, 114, 503, 10.1111/bju.12342 Moschini, 2017, Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy, BJU Int, 120, 69, 10.1111/bju.13683 Tilki, 2017, Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy, BJU Int, 119, 717, 10.1111/bju.13679 Fleischmann, 2009, Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases, Prostate, 69, 352, 10.1002/pros.20889 Palapattu, 2004, Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup, J Urol, 172, 1860, 10.1097/01.ju.0000139886.25848.4a Hofer, 2006, Prognostic factors in lymph node-positive prostate cancer, Urology, 67, 1016, 10.1016/j.urology.2005.10.055 Bianchi, 2016, The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients, Eur Urol, 69, 1142, 10.1016/j.eururo.2015.12.010 Abdollah, 2014, Predicting survival of patients with node-positive prostate cancer following multimodal treatment, Eur Urol, 65, 554, 10.1016/j.eururo.2013.09.025 Fleischmann, 2008, Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival, Histopathology, 53, 468, 10.1111/j.1365-2559.2008.03129.x Abdollah, 2015, More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer, Eur Urol, 67, 212, 10.1016/j.eururo.2014.05.011 Dorin, 2013, Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era, Urol Oncol, 31, 1441, 10.1016/j.urolonc.2012.03.006 Neal, 2020, Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received, Eur Urol, 77, 320, 10.1016/j.eururo.2019.10.030 Yang, 2019, Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9–10 prostate cancer, Eur Urol, 75, 35, 10.1016/j.eururo.2018.08.033 Preisser, 2019, Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer, Prostate, 79, 1832, 10.1002/pros.23908 Moris, 2020, Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review, Eur Urol, 77, 614, 10.1016/j.eururo.2020.01.033 Tilki, 2018, Local treatment for metastatic prostate cancer: a systematic review, Int J Urol, 25, 390, 10.1111/iju.13535 Vale, 2019, Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Dalela, 2017, Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: development and internal validation of a multivariable prognostic model, J Clin Oncol, 35, 1982, 10.1200/JCO.2016.69.9918 Gore, 2017, Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: interim results from the multicenter prospective PRO-IMPACT study, Cancer, 123, 2850, 10.1002/cncr.30665